NEPA is a novel oral fixed-dose combination of netupitant ( NETU ) , a new highly selective neurokinin-@ ( NK@ ) receptor antagonist ( RA ) and palonosetron ( PALO ) , a pharmacologically and clinically distinct @-hydroxytryptamine type @ ( @-HT@ ) RA .